Saturday 17 October 2026
Export INAB’s income statement to Excel — free account
IN8bio, Inc.
INAB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 79.8% and free cash flow fell 1.30%, each against the same quarter a year earlier.
1.11
0.08
−6.72%
Follow INAB
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
8.82 | 4.08 | 4.57 | 3.82 | 17.28 | 7.05 | 1.18 | 12.11 | — |
Net Debt/EBITDA |
1.56 | 0.39 | 0.75 | 0.63 | 2.65 | 2.10 | 0.12 | 2.62 | — |
Debt/Assets |
0.00% | 1.41% | 1.56% | 2.45% | 0.64% | 0.83% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.02 | 0.02 | 0.04 | 0.01 | 0.01 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.65 | 0.79 | 0.78 | 0.85 | 0.92 | 0.69 | 0.81 | 1.10 | — |
Capex/Depreciation |
0.00 | (0.07) | (0.24) | (3.36) | (0.39) | 0.00 | 3.71 | 0.00 | — |
Interest Coverage |
— | — | — | — | — | — | — | (286.29) | — |
| (92.49%) | (154.44%) | (125.90%) | (93.64%) | (135.65%) | 80.09% | 87.64% | 37.20% | — | |
| (73.05%) | (111.38%) | (89.91%) | (75.79%) | (46.42%) | (93.83%) | (168.31%) | (85.12%) | — | |
ROIC |
(2,663.76%) | (524.69%) | (453.60%) | (332.51%) | (639.98%) | (1,067.49%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(73.15%) | (246.39%) | (131.92%) | (137.06%) | (39.80%) | (65.62%) | (1,515.90%) | (46.05%) | — |
Average Days of Receivables |
— | — | — | — | — | — | — | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(2.91) | (13.63) | (24.07) | (39.85) | (41.62) | (62.63) | (41.85) | (0.14) | — |
Cash per Share |
6.19 | 6.23 | 21.40 | 26.04 | 111.51 | 157.98 | 5.74 | 0.26 | — |
Shareholders Equity per Share |
6.30 | 8.11 | 25.07 | 32.56 | 115.01 | 160.85 | (3.26) | 0.24 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
6.30 | 8.11 | 25.07 | 32.56 | 115.01 | 160.85 | (3.26) | 0.24 | — |
Free Cash Flow |
(12.71) | (24.34) | (23.94) | (27.83) | (13.82) | (7.13) | (4.44) | (2.77) | — |
Working Capital |
24.72 | 9.50 | 19.23 | 16.41 | 36.72 | 15.57 | 0.12 | 4.65 | — |
Capital Expenditures |
— | (0.19) | (0.60) | (3.70) | (0.31) | — | 0.36 | (0.76) | — |
Net Current Asset Value |
23.16 | 6.11 | 15.85 | 11.93 | 34.94 | 15.56 | (0.71) | 3.82 | — |
| Other line items | |||||||||
Quick Ratio |
8.57 | 3.61 | 3.95 | 3.12 | 16.41 | 7.00 | 0.94 | 11.98 | — |
Depreciation/Fixed assets |
1.35 | 0.93 | 0.71 | 0.25 | 8.12 | 0.47 | 0.35 | 0.12 | — |
Cash ROIC |
(23.26%) | (93.99%) | (51.22%) | (66.69%) | (18.31%) | (19.55%) | (1,683.71%) | (28.73%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(2.91) | (13.53) | (23.47) | (34.55) | (40.69) | (62.63) | (45.21) | (0.14) | — |
Capex per Share |
0.00 | (0.10) | (0.60) | (5.31) | (0.93) | 0.00 | 3.35 | 0.00 | — |
Average Payables |
0.35 | 0.66 | 1.51 | 1.24 | 0.51 | 0.59 | 0.59 | — | — |
Average Assets |
26.61 | 27.33 | 33.37 | 37.63 | 31.57 | 11.02 | 3.51 | 2.95 | — |
Average Common Equity |
21.02 | 19.71 | 23.83 | 30.46 | 10.80 | (12.91) | (6.75) | (6.75) | — |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
Columns are period end dates